We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect investors to focus on the updates related to Geron Corporation’s (GERN - Free Report) pipeline when it reports fourth-quarter 2022 results.
Shares of GERN have skyrocketed 172.8% in the past year against the industry’s 6.7% fall.
Image Source: Zacks Investment Research
Geron’s surprise history has been mixed, with earnings beating estimates in two of the trailing four quarters while missing the same on the other two occasions. The average surprise is 1.07%. In the last reported quarter, the company reported a negative earnings surprise of 11.11%.
Let’s see how things have shaped up for this announcement.
Factors at Play
In the absence of an approved/marketed product in its portfolio, the focus of the fourth quarter earnings call will be on updates related to Geron Corporation’s pipeline.
Geron Corporation has only one product in its pipeline, imetelstat, which is being developed to target hematologic malignancies.
A telomerase inhibitor exclusively owned by GERN, imetelstat is being evaluated in two separate late-stage studies — IMerge and IMpactMF — in myelodysplastic syndromes (MDS) and myelofibrosis (MF) indications.
Last month, management announced positive top-line data from the IMerge study evaluating imetelstat in lower-risk MDS patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents (ESAs). The study achieved its primary and secondary endpoints of 8-week transfusion independence (TI) and 24-week TI, respectively, with statistically significant and clinically meaningful improvements.
Based on the above data, GERN will initiate a new drug application (NDA) with the FDA in mid-2023 and a marketing authorization application (MAA) with the EMA in second-half 2023 for imetelstat in MDS indication. The FDA has already granted Geron’s request for a rolling NDA submission. Management expects to commercially launch the product next year, with a launch in the U.S. expected early next year.
To ensure a successful commercial launch for imetelstat, Geron recently closed a public offering of common stock for gross proceeds of $227.8 million. This financing, combined with Geron’s existing cash runway, is expected to fund preparatory activities for the potential commercial launch of the drug in the U.S.
Based on Geron’s launch preparations for imetelstat, we expect a significant rise in the company’s total operating expenses in the to-be-reported quarter.
Investors will likely expect an update on the company’s launch plans and regulatory pathway for imetelstat at the upcoming earnings call. The investors would also focus on updates on the IMpactMF study and an early-stage study (IMproveMF) evaluating imetelstat in frontline MF.
Earnings Whispers
Our proven model does not predict an earnings beat for Geron this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not thecase here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Geron has an Earnings ESP of 0.00% as the Most Accurate Estimate and Zacks Consensus Estimate both stand at a loss of 11 cents per share.
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Allogene (ALLO - Free Report) has an Earnings ESP of +25.70% and a Zacks Rank #2.
Shares of Allogene have declined 25.9% in the past year. Earnings of Allogene beat estimates in each of the last four quarters, witnessing a trailing four-quarter positive earnings surprise of 9.44%, on average. In the last reported quarter, Allogene’s earnings beat estimates by 6.45%.
Alnylam Pharmaceuticals (ALNY - Free Report) has an Earnings ESP of +3.00% and a Zacks Rank #3.
Alnylam Pharmaceuticals’stock has surged 51.8% in the past year. Alnylam’s earnings missed estimates in each of the last four quarters, delivering a trailing four-quarter negative earnings surprise of 42.61%, on average. In the last reported quarter, Alnylam Pharmaceuticals’ earnings missed estimates and reported an earnings surprise of 78.49%.
Alnylamis scheduled to release fourth-quarter 2022 results on Feb 23, before market open.
argenx (ARGX - Free Report) has an Earnings ESP of +3.17% and a Zacks Rank #3.
argenx’s stock has risen 34.0% this past year. argenx’s earnings beat estimates in three of the last four quarters and missed the mark on one occasion, delivering a trailing four-quarter earnings surprise of 3.68%, on average.In the last reported quarter, argenx’s earnings missed estimates and reported a negative earnings surprise of 21.71%.
argenx is scheduled to release fourth-quarter 2022 results on Mar 2.
Image: Bigstock
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
We expect investors to focus on the updates related to Geron Corporation’s (GERN - Free Report) pipeline when it reports fourth-quarter 2022 results.
Shares of GERN have skyrocketed 172.8% in the past year against the industry’s 6.7% fall.
Image Source: Zacks Investment Research
Geron’s surprise history has been mixed, with earnings beating estimates in two of the trailing four quarters while missing the same on the other two occasions. The average surprise is 1.07%. In the last reported quarter, the company reported a negative earnings surprise of 11.11%.
Geron Corporation Price and EPS Surprise
Geron Corporation price-eps-surprise | Geron Corporation Quote
Let’s see how things have shaped up for this announcement.
Factors at Play
In the absence of an approved/marketed product in its portfolio, the focus of the fourth quarter earnings call will be on updates related to Geron Corporation’s pipeline.
Geron Corporation has only one product in its pipeline, imetelstat, which is being developed to target hematologic malignancies.
A telomerase inhibitor exclusively owned by GERN, imetelstat is being evaluated in two separate late-stage studies — IMerge and IMpactMF — in myelodysplastic syndromes (MDS) and myelofibrosis (MF) indications.
Last month, management announced positive top-line data from the IMerge study evaluating imetelstat in lower-risk MDS patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents (ESAs). The study achieved its primary and secondary endpoints of 8-week transfusion independence (TI) and 24-week TI, respectively, with statistically significant and clinically meaningful improvements.
Based on the above data, GERN will initiate a new drug application (NDA) with the FDA in mid-2023 and a marketing authorization application (MAA) with the EMA in second-half 2023 for imetelstat in MDS indication. The FDA has already granted Geron’s request for a rolling NDA submission. Management expects to commercially launch the product next year, with a launch in the U.S. expected early next year.
To ensure a successful commercial launch for imetelstat, Geron recently closed a public offering of common stock for gross proceeds of $227.8 million. This financing, combined with Geron’s existing cash runway, is expected to fund preparatory activities for the potential commercial launch of the drug in the U.S.
Based on Geron’s launch preparations for imetelstat, we expect a significant rise in the company’s total operating expenses in the to-be-reported quarter.
Investors will likely expect an update on the company’s launch plans and regulatory pathway for imetelstat at the upcoming earnings call. The investors would also focus on updates on the IMpactMF study and an early-stage study (IMproveMF) evaluating imetelstat in frontline MF.
Earnings Whispers
Our proven model does not predict an earnings beat for Geron this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not thecase here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Geron has an Earnings ESP of 0.00% as the Most Accurate Estimate and Zacks Consensus Estimate both stand at a loss of 11 cents per share.
Zacks Rank: Geron has a Zacks Rank #2, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Allogene (ALLO - Free Report) has an Earnings ESP of +25.70% and a Zacks Rank #2.
Shares of Allogene have declined 25.9% in the past year. Earnings of Allogene beat estimates in each of the last four quarters, witnessing a trailing four-quarter positive earnings surprise of 9.44%, on average. In the last reported quarter, Allogene’s earnings beat estimates by 6.45%.
Alnylam Pharmaceuticals (ALNY - Free Report) has an Earnings ESP of +3.00% and a Zacks Rank #3.
Alnylam Pharmaceuticals’stock has surged 51.8% in the past year. Alnylam’s earnings missed estimates in each of the last four quarters, delivering a trailing four-quarter negative earnings surprise of 42.61%, on average. In the last reported quarter, Alnylam Pharmaceuticals’ earnings missed estimates and reported an earnings surprise of 78.49%.
Alnylamis scheduled to release fourth-quarter 2022 results on Feb 23, before market open.
argenx (ARGX - Free Report) has an Earnings ESP of +3.17% and a Zacks Rank #3.
argenx’s stock has risen 34.0% this past year. argenx’s earnings beat estimates in three of the last four quarters and missed the mark on one occasion, delivering a trailing four-quarter earnings surprise of 3.68%, on average.In the last reported quarter, argenx’s earnings missed estimates and reported a negative earnings surprise of 21.71%.
argenx is scheduled to release fourth-quarter 2022 results on Mar 2.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.